The 17 linked references in paper K. Mukhin Yu., O. Pylaeva A., M. Bobylova Yu., N. Freydkova V., L. Glukhova Yu., M. Abramov O., К. Мухин Ю., О. Пылаева А., М. Бобылова Ю., Н. Фрейдкова В., Л. Глухова Ю., М. Абрамов О. (2018) “Эффективность и переносимость руфинамида в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Святителя Луки) // Efficacy and tolerability of rufinamide in the treatment of epilepsy (experience of the Svt. Luka’s Institute of Child Neurology and Epilepsy)” / spz:neicon:rjdn:y:2018:i:2:p:7-19

  1. DOI: 10.1111/bcp.12479. 14. Cheng-Hakimian A., Anderson G.D., Miller J.W.
  2. DOI: 10.1016/j.ejpn.2014.05.008. 16. Coppola G., Grosso S., Franzoni E. et al. Rufinamide in children and adults with Lennox–Gastaut syndrome: first Italian multicenter experience. Seizure 2010;19(9):587–91.
  3. DOI: 10.1016/j.seizure.2010.09.008. 17. Cross J.H., Auvin S., Falip M. et al. Expert opinion on the management of Lennox– Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017;8:505. PMID: 29085326.
  4. DOI: 10.3389/fneur.2017.00505. 18. Gastaut H., Roger J., Soulayrol R. et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox
  5. PMID: 21189229. DOI: 10.1016/j.yebeh.2010.11.014. 22. Kim S.H., Lee J.H., Ryu H.W. et al. Short-term efficacy and tolerability of rufinamide adjunctive therapy in childre
  6. PMID: 23531645. DOI: 10.1684/ epd.2013.0557. 23. Kluger G., Haberlandt E., Kurlemann G. et al. First European long-term experience with the orphan dru
  7. DOI: 10.1016/j.yebeh.2010.01.005. 24. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-te
  8. PMID: 20199521. DOI: 10.1111/j.1600-0404.2010.01334.x. 25. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.
  9. DOI: 10.1586/14737175.6.3.397. 27. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with
  10. DOI: 10.1016/j.clineuro.2012.09.021. 28. McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safet
  11. DOI: 10.1007/s40120-016-0041-9. 29. Moavero R., Santarone M.E., Galasso C., Curatolo P.
  12. DOI: 10.1016/j.braindev.2017.01.006. 30. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Long-term safety and seizure outcome in Japanese patients wi
  13. DOI: 10.1016/j.eplepsyres.2016.01.002. 31. Ostendorf A.P., Ng Y.T. Treatmentresistant Lennox–Gastaut syndrome: therapeutic trends, challenges and
  14. DOI: 10.2147/NDT.S115996. 32. Vendrame M., Loddenkemper T., Gooty V.D. et al. Experience with rufinamide in a pediatric population: a single center's experience. Pedi
  15. PMID: 20691934. DOI: 10.1016/j.pediatrneurol.2010.04.003. 33. Wheless J. W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled a
  16. DOI: 10.1177/0883073809350508. 34. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox– Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2
  17. DOI: 10.2165/11586920-000000000-00000.